India is one of the world’s largest suppliers of low-cost vaccinations. India produces 60% of the world’s vaccinations, accounting for up to 70% of WHO demand for Diphtheria, Tetanus, and Pertussis (DPT) and Bacillus Calmette-Guérin (BCG) vaccines and 90% of WHO demand for measles vaccine.
Globally, the Indian pharmaceutical sector is recognized for its generic pharmaceuticals, India’s pharmaceutical sector is the world’s third biggest in terms of volume and the 14th largest in terms of value. The pharmaceutical industry presently accounts for around 1.72% of the country’s GDP.
As per the report, The Indian pharmaceutical industry is projected to grow at a CAGR of over 10% to reach a size of $130 billion by 2030.
Here are the three Fundamentally strong Pharma Stocks under Rs 100
Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd is a small-cap stock with a market capitalization of Rs 548 crore. On Friday, Company shares closed at Rs 92.80 a share, down 0.64 percent from the previous close of Rs 93.40.
Ind-Swift Laboratories Ltd’s revenue has declined by 7 percent year on year, from Rs 310 crore in Q2FY23 to Rs 289 crore in Q2FY24. During the same period, net profit has jumped by 24 percent from Rs 25 crore to Rs 31 crore.
Ind-Swift Laboratories Ltd shares have gained 33 percent in the last six months and 46 percent in the last year.
According to a recent shareholding pattern, the company promoters hold a 42 percent stake in the company, Domestic institutional investors hold 19.49 percent and retail investors hold a 38.34 percent stake.
Ind-Swift Laboratories Ltd is engaged in manufacturing Active Pharmaceutical Ingredients and Advanced Intermediates and providing Contract Research and Manufacturing Services.
Morepen Laboratories Ltd
Morepen Laboratories Ltd is a small-cap stock with a market capitalization of Rs 2,267 crore. On Friday, Company shares closed at Rs 44.35 a share, up 1.03 percent from the previous close of Rs 43.90.
Morepen Laboratories Ltd’s revenue has increased by 5 percent year on year, from Rs 402 crore in Q2FY23 to Rs 421 crore in Q2FY24. In the same time frame, net profit has jumped by 40 percent from Rs 15 crore to Rs 21 crore.
Morepen Laboratories Ltd shares have gained 75 percent in the last six months and 54 percent in the last year.
According to a recent shareholding pattern, the company promoters hold a 38.22 percent stake in the company, Domestic institutional investors hold 2.28 percent and retail investors hold a 58.2 percent stake.
Morepen Laboratories Ltd is engaged in manufacturing, producing, developing, and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and Home Health products.
Alembic Ltd.
Alembic Ltd is a small-cap stock with a market capitalization of Rs 2,182 crore. On Friday, Company shares closed at Rs 85 a share, up 2.90 percent from the previous close of Rs 82.60.
Alembic Ltd’s revenue has fallen by 14 percent year on year, from Rs 37 crore in Q2FY23 to Rs 32 crore in Q2FY24. During the same period, net profit has declined by 16 percent from Rs 61 crore to Rs 51 crore.
Alembic Ltd shares have gained 28 percent in the last six months and 17 percent in the last year.
According to a recent shareholding pattern, the company promoters hold a 70.88 percent stake in the company, Domestic institutional investors hold 3.41 percent and retail investors hold a 24.86 percent stake.
Alembic Limited is engaged in the businesses of Pharmaceuticals, Real Estate, and Power Assets.
Written By Omkar Chitnis
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
